rabies immune globulin, human (RIG) (HyperRAB, HyperRAB S/D, Imogam, Imogam Rabies HT, Imovax Rabies, RIG)

Dosing and uses of HyperRAB, HyperRAB S/D (rabies immune globulin, human (RIG))

• Adult
• Pediatric

 

Adult dosage forms and strengths

injectable solution

• 150 International Units/mL (2mL vial)
• 150 International Units/mL (10mL vial)

 

Rabies, Postexposure Prophylaxis

20 International Unit/kg, infiltrate locally around bite

If full dose infiltration not possible, give rest IM in gluteal or lateral thigh muscle

 

Administration

Because of injury risk to sciatic nerve, avoid central gluteal region; administer only in upper, outer quadrant

Always administer in conjunction with rabies vaccine (HDCV)

Preferably give concomitantly with vaccine but may be given thru 7th day after first dose of vaccine

Avoid repeated dose once vaccine treatment has started

 

Other Information

Give with 1st dose of vaccine as soon as possible post-exposure

 

Pediatric dosage forms and strengths

injectable solution

• 150 International Units/mL (2mL vial)
• 150 International Units/mL (10mL vial)

Same as adult dosing; 20 International Unit/kg, infiltrate locally around bite

 

HyperRAB, HyperRAB S/D (rabies immune globulin, human (RIG)) adverse (side) effects

Frequency not defined

Injection site pain

N/V

Fever

Lethargy

Chest tightness

Rash

Headache

Anaphylaxis

Angioneurotic edema

Nephrotic syndrome (rare)

 

Warnings

Contraindications

None

 

Cautions

Thrombocytopenia, bleeding disorders, or prior allergic reactions to immune globulins

Avoid live vaccinations for 3 mth

Do NOT give IV

Discard unused portions

 

Pregnancy and lactation

Pregnancy category: C

Lactation: no adverse events reported; may be excreted in breast milk

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of HyperRAB, HyperRAB S/D (rabies immune globulin, human (RIG))

Half-Life: 21 d

Peak Plasma Time: 2-13 d

 

Mechanism of action

Human immune globulins from donors